Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adimab, GSK expand collaboration for new bispecific antibodies
As part of the deal, Adimab will build a new custom library and transfer it to GSK for its internal use in the discovery of bispecifics. The new
As part of the deal, Adimab will build a new custom library and transfer it to GSK for its internal use in the discovery of bispecifics. The new
The collaboration will further advance FMI’s position in molecular information and genomic analysis while providing Roche an opportunity to optimize the identification and development of new treatment options
Established in 2012, Melanovus obtained an exclusive global license from the Penn State Research Foundation to a library of compounds and related intellectual property. These compounds originate from
Currently, the company is screening patients for a Phase II trial of the oral formulation of SCY-078 and expects to enroll the first patient in the first quarter
The deal approved by the boards of directors from both companies will see Shire pay $46 per share in cash for NPS, which has expertise in gastrointestinal (GI)
As part of the deal, Precision’s NanoAssemblr platform will be used to manufacture GMP batches to support clinical trials and commercial development for RNA medicines developed using Arcturus’
Under the deal, discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a two-year period to meet predefined milestones, while Bayer will be
The acquisition is centered on development of the UK firm’s Phase II clinical candidate CNV1014802, which has showed clinical activity in proof of concept trials for trigeminal neuralgia
Both the trials, which met their primary efficacy endpoints, compared the reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks with alirocumab versus placebo in these
Currently, Syndax is developing entinostat, a Class I selective histone deacetylase (HDAC) inhibitor, in the US and Europe in combination with hormone therapy for advanced breast cancer and